Published in Clin Cancer Res on April 21, 2009
Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila) (2009) 1.75
Performing vaginal lavage, crystal violet staining, and vaginal cytological evaluation for mouse estrous cycle staging identification. J Vis Exp (2012) 1.31
Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res (2010) 1.07
Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS One (2011) 0.96
New insights on the role of hormonal therapy in ovarian cancer. Steroids (2013) 0.94
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res (2012) 0.91
14-3-3 σ expression effects G2/M response to oxygen and correlates with ovarian cancer metastasis. PLoS One (2011) 0.88
Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol Oncol (2014) 0.87
17β-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo. Int J Cancer (2014) 0.87
The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. Biomed Res Int (2015) 0.85
The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol (2011) 0.82
Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer. J Steroid Biochem Mol Biol (2014) 0.81
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res (2015) 0.79
17β Hydroxysteroid dehydrogenase type 12 (HSD17B12) is a marker of poor prognosis in ovarian carcinoma. Gynecol Oncol (2012) 0.78
Estrogen responsiveness of the TFIID subunit TAF4B in the normal mouse ovary and in ovarian tumors. Biol Reprod (2013) 0.78
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice. J Ovarian Res (2014) 0.75
Protective Effect of Progesterone during Pregnancy against Ovarian Cancer. J Cancer Prev (2013) 0.75
Regulation of semaphorin 4D expression and cell proliferation of ovarian cancer by ERalpha and ERbeta. Braz J Med Biol Res (2017) 0.75
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
MAP kinase signalling pathways in cancer. Oncogene (2007) 8.52
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res (2006) 3.58
Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res (2003) 2.32
Menstrual influence on surgical cure of breast cancer. Lancet (1989) 2.08
A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett (1987) 1.94
Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc Natl Acad Sci U S A (2000) 1.72
A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology (1995) 1.70
Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res (2007) 1.66
Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology (1993) 1.59
Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem (2004) 1.59
Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res (2000) 1.55
Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem (2007) 1.54
Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res (2001) 1.51
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res (2007) 1.51
Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol (2003) 1.44
Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer (2009) 1.39
Promotion of the Whitten effect in female mice by synthetic analogs of male urinary constituents. Proc Natl Acad Sci U S A (1986) 1.36
Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update (2006) 1.14
Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer (1997) 1.10
Morphological changes in breast tissue with menstrual cycle. Mod Pathol (2002) 1.08
Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect (2000) 1.07
Estrous cycle influences organ-specific metastasis of B16F10 melanoma cells. Cancer Res (2003) 1.03
Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol (1997) 1.03
Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol (2002) 1.02
Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett (2005) 1.01
Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer (2005) 1.00
Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res (2005) 1.00
Inhibitory effects of progesterone on plasma membrane fluidity and tumorigenic potential of ovarian epithelial cancer cells. Exp Biol Med (Maywood) (2003) 0.99
Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology (2001) 0.99
Thombospondin-1 disrupts estrogen-induced endothelial cell proliferation and migration and its expression is suppressed by estradiol. Mol Cancer Res (2004) 0.98
Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst (2002) 0.97
The pattern of estradiol and progesterone differs in serum and tissue of benign and malignant ovarian tumors. Int J Oncol (2002) 0.96
Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis. Mol Cancer Ther (2005) 0.96
Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab (1992) 0.95
Effects of progesterone on ovarian tumorigenesis in xenografted mice. Cancer Lett (2005) 0.95
Menstrual timing of breast cancer surgery. Am J Surg (1998) 0.94
Estradiol increases VEGF in human breast studied by whole-tissue culture. Cell Tissue Res (2006) 0.91
Natural killer cell activity: age, estrous- and circadian-stage dependence and inverse correlation with metastatic potential. J Natl Cancer Inst (1988) 0.90
Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene (2003) 0.88
Non-genomic effects of 17beta-estradiol in activation of the ERK1/ERK2 pathway induces cell proliferation through upregulation of cyclin D1 expression in bovine artery endothelial cells. Gynecol Endocrinol (2007) 0.87
High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane. J Steroid Biochem Mol Biol (2001) 0.87
Estradiol enhances endothelial cell interactions with extracellular matrix proteins via an increase in integrin expression and function. Angiogenesis (1999) 0.86
Biochemistry of aromatase: significance to female reproductive physiology. Cancer Res (1982) 0.86
Oestrogen and endothelial cell angiogenic activity. Clin Exp Pharmacol Physiol (1996) 0.86
Fertility cycle influence on surgical breast cancer cure. Breast Cancer Res Treat (2002) 0.86
The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo. Clin Cancer Res (2004) 0.84
Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium. Reprod Biol Endocrinol (2003) 0.84
Sex cycle modulates cancer growth. Breast Cancer Res Treat (2005) 0.83
Suppression of the transformed phenotype and induction of differentiation-like characteristics in cultured ovarian tumor cells by chronic treatment with progesterone. Mol Carcinog (2003) 0.81
Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer. Anticancer Drugs (2001) 0.80
[The effect of progesterone on proliferation and apoptosis in ovarian cancer cell]. Zhonghua Fu Chan Ke Za Zhi (2000) 0.80
Role of endocrine status and cell type in adhesion of human endometrial cells to the peritoneum in nude mice. Fertil Steril (2002) 0.79
Hemostatic effects of high-dose megestrol acetate therapy in patients with advanced gynecological cancer. Gynecol Endocrinol (2001) 0.78
Biological effects of progestins in breast cancer. Gynecol Endocrinol (1999) 0.77
[Effect of estrogen and progesterone on the expression of VEGF mRNA in epithelial ovarian cancer cell line]. Zhonghua Zhong Liu Za Zhi (2004) 0.76
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res (2006) 3.58
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
A functional genomic perspective on human well-being. Proc Natl Acad Sci U S A (2013) 2.98
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Reciprocal regulation of the neural and innate immune systems. Nat Rev Immunol (2011) 2.87
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res (2006) 2.32
Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A (2010) 2.31
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res (2005) 2.16
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Platelets increase the proliferation of ovarian cancer cells. Blood (2012) 1.97
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One (2010) 1.87
Mindfulness-Based Stress Reduction training reduces loneliness and pro-inflammatory gene expression in older adults: a small randomized controlled trial. Brain Behav Immun (2012) 1.86
Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res (2011) 1.84
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res (2006) 1.84
Social stress up-regulates inflammatory gene expression in the leukocyte transcriptome via β-adrenergic induction of myelopoiesis. Proc Natl Acad Sci U S A (2013) 1.81
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer (2005) 1.79